Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant
Status:
Recruiting
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
This study is a Phase 2 multicenter study with a Safety Lead-in evaluating safety and
efficacy of MT-401 administration to patients with AML, who have received their first
allogeneic HSCT. The dose administered is 50 x 10^6 cells (flat dosing).